Can tirzepatide cause pancreatitis?
Pancreatitis is a labeled warning for tirzepatide, but the absolute risk is low. Know the red-flag symptoms and who should be most cautious.
Updated May 27, 2026 · 4 min read
Yes — pancreatitis is listed in tirzepatide's prescribing information as a warning, and cases have been reported. That said, the absolute risk is low, and the association between GLP-1 class drugs and pancreatitis is smaller in real-world data than early concerns suggested. The most important thing to know is what pancreatitis actually feels like, because it's one side effect you don't want to wait out.
What the prescribing information says
Eli Lilly's Mounjaro and Zepbound labels both carry a warning (not a black-box warning, which is the FDA's highest severity level) about acute pancreatitis. The label advises:
- Discontinue tirzepatide promptly if pancreatitis is suspected
- Do not restart if pancreatitis is confirmed
- Exercise caution in patients with a history of pancreatitis
This is a class-wide warning shared by semaglutide (Ozempic/Wegovy) and other GLP-1 receptor agonists. The mechanism isn't fully established, but GLP-1 receptors are expressed in pancreatic tissue, and the theory is that chronic GLP-1 receptor stimulation may affect pancreatic exocrine function in susceptible individuals.
What the actual risk looks like
The numbers are genuinely hard to pin down, and large observational studies have shown conflicting results. Some key points:
- Early meta-analyses suggested a possible 2–3× increased pancreatitis risk with GLP-1 agonists; more recent and larger studies have found smaller or no significant increase
- People with obesity and type 2 diabetes have baseline elevated pancreatitis risk regardless of medication — separating drug effect from underlying disease risk is genuinely difficult
- In the SURMOUNT (tirzepatide weight) and SURPASS (tirzepatide diabetes) trial programs, pancreatitis rates were low and did not show a dramatic signal relative to placebo
The bottom line: the absolute risk is small, but "small" doesn't mean zero. Pancreatitis is a serious enough condition that the warning is clinically meaningful even at low absolute rates.
The symptoms that should make you stop and call a doctor
Pancreatitis has a recognizable presentation. If you experience these on tirzepatide, stop the injection and seek immediate medical attention — do not wait for the next dose:
- Severe, persistent pain in the upper abdomen, often radiating through to the back
- Nausea and vomiting that's distinctly worse than typical GLP-1 side-effect nausea
- Pain that worsens after eating
This is the critical distinction: GLP-1 nausea is common, usually dose-related, and fades. Pancreatitis pain is typically severe, continuous, and feels nothing like nausea — it's a visceral pain that sits in the mid-abdomen and back. If you're unsure, err toward getting evaluated. Mild pancreatitis treated early stays mild; ignored, it can escalate quickly.
Who should be most cautious
History of pancreatitis. The prescribing information explicitly recommends caution. Some clinicians avoid GLP-1 class drugs entirely in patients with prior pancreatitis; others may prescribe with close monitoring. This is a conversation to have explicitly with your prescriber, not an assumption either way.
Gallstones or a history of gallbladder disease. Gallstones are a leading cause of pancreatitis, and rapid weight loss (including from GLP-1 medications) slightly increases gallstone formation risk. If you have known gallstones and start tirzepatide, your clinician should know.
Heavy alcohol use. Alcohol is a major independent risk factor for pancreatitis. Combined with any medication that also carries a pancreatitis warning, the calculus changes.
High triglycerides. Very elevated triglycerides (typically above 1,000 mg/dL) can independently cause pancreatitis. Tirzepatide often reduces triglycerides, which is actually beneficial here, but if you're starting with severely elevated levels it's worth discussing with your prescriber.
What to tell your doctor before starting
Bring up:
- Any prior episode of pancreatitis (even mild, even years ago)
- Any current gallbladder issues
- Your current triglyceride level if you know it
Your prescriber should have this information anyway from a standard intake, but if you're getting tirzepatide through a telehealth platform with a shorter intake form, make sure these items are communicated explicitly.
The GLP-1 class comparison
The pancreatitis warning applies to the entire GLP-1 receptor agonist class — semaglutide, liraglutide, exenatide, dulaglutide, and tirzepatide all carry it. Tirzepatide is not uniquely riskier than semaglutide based on available data. If you're choosing between GLP-1 options for other reasons, pancreatitis risk alone isn't a differentiating factor.
For the full side-effect picture for tirzepatide, see the tirzepatide side effects vs semaglutide comparison. For the general pancreatitis deep-dive, see the GLP-1 and pancreatitis page.